On 11 March 2020, the World Health Organization declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak a pandemic due to the constantly increasing number of cases worldwide. Patients with SARS-CoV-2 infection can develop coronavirus disease 2019 (COVID-19), which results in high rates of hospitalization and intensive care unit (ICU) admission. This exponential surge of patients requiring ICU admission for respiratory support forced health and government officials to rapidly respond to the outbreaks, by dedicating most of the health resources to treat these high-risk patients.¹ At the same time, there is an urgent need to manage cardiovascular time-dependent emergencies, including acute myocardial infarction, with appropriate standards of care and dedicated preventive measures and pathways against the risk of SARS-CoV-2 infection.² Thus, although fully recognizing the unprecedented strain on world healthcare systems of COVID-19, the cardiology community is striving to guarantee the best and safest treatment for all ST-elevation myocardial infarction (STEMI) patients.² Notably, in these patients, the early implementation of pharmacological or mechanical reperfusion therapies is critical, and significantly improves survival by rapidly re-establishing coronary blood flow within the occluded infarct-related artery.³

中文翻译：

---

在ST抬高型心肌梗死中，治疗时间仍然很重要：呼吁在COVID-19大流行期间维持治疗有效性

2020年3月11日，世界卫生组织宣布严重急性呼吸综合征冠状病毒2（SARS-CoV-2）爆发是大流行病，原因是全球病例数不断增加。患有SARS-CoV-2感染的患者可能会发展冠状病毒病2019（COVID-19），这导致高住院率和重症监护病房（ICU）入院。需要ICU入院呼吸支持的患者数量激增，迫使卫生和政府官员通过将大部分卫生资源用于治疗这些高风险患者，迅速应对疫情。^1个同时，迫切需要通过适当的护理标准和专门的预防措施以及针对SARS-CoV-2感染风险的途径来应对包括急性心肌梗死在内的心血管时间依赖性紧急事件。²因此，尽管充分认识到世界上对COVID-19的医疗系统造成了前所未有的压力，但心脏病学界仍在努力为所有ST段抬高型心肌梗死（STEMI）患者提供最佳和最安全的治疗方法。²值得注意的是，在这些患者中，药物或机械再灌注疗法的早期实施至关重要，并且可以通过在梗塞相关动脉内快速重建冠状动脉血流来显着提高生存率。³